Good
Mostly Aligned
Patient Risk:
Low
Summary
Indication and migraine-related claims align well with the label. Several insomnia-related and CNS effect claims are supported, but there are multiple notable omissions (pregnancy/contraindications/boxed warnings/pediatric safety) and several stated CNS sleep claims are not consistently supported by the label. Overall, the assessment is Good with important safety/label completeness gaps.
Category Scores
Accurate Statements
Propranolol is used for migraines.
Indications and Usage
Propranolol reduces heart rate.
Adverse Reactions
Propranolol crosses the blood-brain barrier.
Distribution
Propranolol insomnia risk <1%.
Adverse Reactions
Propranolol is a non-selective beta-blocker.
Clinical Pharmacology – Mechanism of Action
Unsupported Statements
Propranolol is used for high blood pressure.
Label includes hypertension indications; however, the claim here is broader and may be considered unsupported in the specific phrasing provided if not explicitly listed in the extracted claims as per the evaluation set.
Propranolol reduces physical symptoms of stress that can disrupt rest.
Not described as a label indication or target effect related to sleep disruption; unsupported by Indications/Usage.
Individual sensitivity to beta-blockade can alter melatonin production.
Not described in the label; unsupported.
Individual sensitivity to beta-blockade can cause vivid dreams/nightmares in 1-10% of cases.
No labeled frequency for vivid dreams/nightmares with propranolol; not reported as a quantified signal in the label.
Dose timing: Taking propranolol late in the day might interfere with sleep onset for some.
Label discusses dosing but does not mandate late-evening dosing changes; not a blanket instruction.
Withdrawal: Abruptly stopping can trigger rebound insomnia.
Withdrawal signals are not described as insomnia in the boxed/discontinuation context; not a standard label warning for rebound insomnia.
Alcohol or caffeine should be avoided, which worsen interactions.
Label discusses drug interactions but does not universally mandate avoidance of alcohol or caffeine.
Try a selective beta-blocker like metoprolol, which has fewer CNS effects.
Label does not prescribe alternatives; not a formal label claim for propranolol.
Nightmares or altered dreams are reported more often than insomnia, due to beta-2 receptor blockade affecting REM sleep.
No label support for this mechanism or precedence; unsupported.
No strong link to chronic insomnia in long-term studies.
Label does not state such a conclusion in this wording; unsupported as a generalized safety claim.
Effects usually resolve with dose adjustment.
Not explicitly stated as a general instruction in the label.
Switch to morning dosing.
No universal directive to switch dosing to morning; not a blanket label instruction.
Lower the dose.
Dose reduction is a standard option in management; however, the claim as a standalone instruction is not specifically framed in the label without context.
Try a selective beta-blocker like metoprolol, which has fewer CNS effects.
Not described as a recommendation in the propranolol label.
Pregnancy risk
Pregnancy/pregnancy category information is not addressed in the claims section here; omitted.
Contradictions
Low
AI Statement
Propranolol does not typically cause insomnia.
Label Reference
Adverse Reactions
Low
AI Statement
Nightmares or altered dreams are reported more often than insomnia, due to beta-2 receptor blockade affecting REM sleep.
Label Reference
Adverse Reactions
Important Omissions
Pregnancy risk and fetal/neonatal considerations
Importance:
High
Contraindications (e.g., sinus bradycardia, AV block > first degree, uncompensated heart failure, cardiogenic shock, hypersensitivity)
Importance:
High
Boxed warnings
Importance:
High
Pediatric safety and dosing
Importance:
Moderate
Dosing safety and discontinuation/tapering guidance
Importance:
High
Alcohol/caffeine interactions guidance
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Label includes several CNS adverse events (insomnia, vivid dreams) but provides no broad safety red flags beyond standard beta-blocker precautions; major risks (bradycardia, hypotension, heart block) are acknowledged in adverse reactions; omissions identified relate to non-clinically dangerous but important label sections (pregnancy, contraindications).
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Important safety label areas (pregnancy, contraindications, boxed warnings, pediatric safety) are not addressed in the claims; consider explicit inclusion.
Suggested Improvement
Incorporate comprehensive safety sections (pregnancy risk, contraindications, boxed warnings, pediatric safety) and explicit guidance on tapering/discontinuation and substance interactions (e.g., alcohol/caffeine) to improve label-alignment.